Compare BHP Billiton Limited (BHP) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs Moderna, Inc. — how do they compare? BHP Billiton Limited trades at $91.5 (market cap $229.15B), while Moderna, Inc. trades at $60.3 (market cap $24.18B). The key difference: BHP Billiton Limited is far larger — about 9.5× Moderna, Inc.'s market cap, and BHP Billiton Limited pays a 2.95% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| BHP | MRNA | |
|---|---|---|
Market Cap | $229.15B | $24.18B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $81.80 |
52-Week Low | $52.14 | $22.36 |
Enterprise Value | $243.35B | $20.33B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.61, up 0.22% with a bullish technical signal supported by moving averages. The company reported mixed Q4 2025 earnings, missing EPS estimates but maintaining strong profitability with 18.97% net margins. Recent operational challenges include strikes at Port Hedland iron ore operations, while copper production declines in Chile. Valuation metrics show a P/E of 22.36 and P/B of 4.54, reflecting premium pricing relative to historical levels.
The outlook remains cautiously optimistic with analyst consensus leaning hold (64.52%) amid labor disputes and production volatility. Key opportunities include exposure to AI-driven copper demand growth, while risks center on strike impacts and fluctuating commodity prices. The stock's current technical strength faces fundamental headwinds from operational disruptions.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
